Biogen (BIIB) Stock Price
Biogen Price
Revenue has compounded at 7.1% per year over the past 19 years to 9.89 B USD. Earnings per share have grown at 14.9% per year over the last 19 years. Biogen's net margin stands at 13.1%, down from 14.2% several years earlier. Analysts set a median price target of 240.00 USD, implying 9.2% above the current price. Of 43 analysts, 30 rate the stock a buy — an overall Buy consensus.
Biogen stock price
Biogen business model & stock analysis
Frequently asked questions about Biogen
Biogen Inc.'s business model revolves around the development, manufacturing, and commercialization of therapies for neurological, autoimmune, and rare diseases. As a leading biotechnology company, Biogen focuses on creating innovative treatments to address unmet medical needs. With a diverse portfolio encompassing multiple therapeutic areas, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, Biogen strives to improve patients' lives worldwide. Through strategic collaborations and scientific advancements, the company continues to invest in cutting-edge research and development to bring transformative therapies to patients, making Biogen a key player in the biopharmaceutical industry.
Biogen Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Biogen Inc in the market are Amgen Inc, AbbVie Inc, and Gilead Sciences Inc.
Biogen Inc is a renowned biotechnology company with a rich history and impressive background. Founded in 1978, Biogen has consistently aimed to develop innovative therapies for patients facing serious neurological and neurodegenerative diseases. Over the years, the company has made significant contributions to the field of biotechnology, especially in areas like multiple sclerosis (MS) and spinal muscular atrophy (SMA). Biogen's mission involves relentless pursuit of scientific excellence and commitment to improving patients' lives. With a diverse portfolio of groundbreaking therapies and a global presence, Biogen continues to be a leading player in the biotechnology industry, dedicated to transforming the course of human health.
Biogen Inc, a leading biotechnology company, has achieved several significant milestones. Notably, the company successfully introduced the first treatment for multiple sclerosis, revolutionizing the lives of patients worldwide. Biogen also developed ground-breaking therapies for spinal muscular atrophy, empowering patients with this rare genetic disease. Moreover, the company made strides in neurology and introduced medications addressing Alzheimer's disease and Parkinson's disease. Biogen's commitment to innovation has led to these remarkable achievements, positioning the company as a pioneer in the biotech industry. As an influential player, Biogen Inc continues to drive advancements in healthcare, improving the quality of life for countless individuals.
Biogen Inc operates in several countries and regions around the world. As a leading biotechnology company, Biogen Inc has a significant presence in the United States, where it is headquartered. Additionally, Biogen Inc has operations and presence in Europe, including countries such as Germany, France, Italy, and Switzerland. The company also serves markets in Asia, with a presence in Japan, South Korea, and several other countries in the region. Biogen Inc's global footprint allows it to reach a wide range of patients and healthcare providers, ensuring its innovative therapies and treatments are accessible to individuals in various parts of the world.
Biogen Inc is a biotechnology company known for its commitment to scientific innovation and improving patients' lives. Guided by their corporate philosophy, Biogen Inc strives to discover, develop, and deliver innovative therapies for neurological, autoimmune, and rare diseases. The company values integrity, diversity, and inclusion in their pursuit of breakthrough treatments, always putting patients at the forefront. Biogen Inc's collaborative approach, dedication to scientific rigor, and passion for making a difference have earned it a leading position in the biotech industry. With a focus on transformative therapies, Biogen Inc continues to drive advancements in healthcare and empower patients worldwide.
Analysts currently set an average price target of 238.69 USD for the Biogen stock (median: 240.00 USD), implying +8.6 % versus the latest price. The consensus is based on 43 analyst ratings.
43 analysts currently rate the Biogen stock: 30 recommend buying, 12 holding and 1 selling. For 2026, analysts expect Biogen to generate revenue of 10.45 B USD and earnings per share of 12.42 USD.
Converted at the current exchange rate, the Biogen share trades at 195.45 EUR (219.88 USD).
The Biogen share (BIIB) is listed on 11 stock exchanges, including: NASDAQ (BIIB), London (0R1B.L), SIX (Zürich) (BIIB.SW), XETRA (IDP.DE), Frankfurt (IDP.F), München (IDP.MU), Düsseldorf (IDP.DU), Hamburg (IDP.HM).
Biogen Inc. is a biopharmaceutical company specializing in the research, development, and marketing of therapies for neurological, hematological, and autoimmune diseases. It was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen currently has three main business segments: Neurology, Hematology, and Biosimilars. The Neurology division focuses on the development and marketing of drugs for the treatment of Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and other neurological disorders. The Hematology division focuses on the development of therapies for blood diseases such as Hemophilia and Sickle Cell Anemia. The Biosimilars division focuses on the development of generic versions of biological drugs. Biogen has partnerships with other major companies such as Eisai Co. and Ionis Pharmaceuticals to work on the development of new drugs and therapies. The company's business model is based on the sale of patented drugs and the development of new therapies. In summary, Biogen is a biopharmaceutical company specializing in the development and marketing of therapies for neurological, hematological, and autoimmune diseases, aiming to improve the lives of patients worldwide.
The expected revenue of Biogen is 10.45 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Biogen is 1.83 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Biogen is currently 17.71. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biogen stock.
The price-to-sales ratio (P/S) of Biogen is currently 3.09. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biogen stock.
The Eulerpool Quality Score for Biogen is 3/10.
The ISIN of Biogen is US09062X1037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biogen is 789617. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biogen is BIIB. The ticker symbol is used to trade Biogen shares on the stock exchange.
Biogen stock
Biogen Ticker
Biogen FIGI
All fundamentals and in-depth analysis of Biogen
Our stock analysis for Biogen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biogen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.